| Identification | Back Directory | [Name]
TL13-112 | [CAS]
2229037-19-6 | [Synonyms]
TL13-112
Acetamide, N-[2-[2-[2-[4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-1-piperidinyl]ethoxy]ethoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- | [Molecular Formula]
C49H60ClN9O10S | [MDL Number]
MFCD31812614 | [MOL File]
2229037-19-6.mol | [Molecular Weight]
1002.57 |
| Chemical Properties | Back Directory | [density ]
1.350±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
10.73±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984)[1]. | [IC 50]
Cereblon: 2.4 μM (IC50) | [storage]
Store at -20°C | [References]
[1] Powell CE, et al. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).J Med Chem.?2018?May 10;61(9):4249-4255. DOI:10.1021/acs.jmedchem.7b01655 |
|
|